Venus Medtech, a Hangzhou-based cardiovascular device company, raised $37 million from Goldman Sachs. Venus specializes in artificial cardiac valves along with stents and other CV products. Usually, Goldman Sachs makes investments in a company prior to an IPO, so apparently Venus is planning a public offering. Venus also announced it established a heart valve research center in partnership with the Second Affiliated Hospital of Zhejiang University School of Medicine.
